Articles published by Scholar Rock

< Previous 1 2 3 4 5 6 Next >

Scholar Rock to Present at Upcoming Investor Conferences

November 03, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

October 20, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 16, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

October 08, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 21, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

September 11, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

September 02, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock to Present at Upcoming Investor Conferences

August 27, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

August 21, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

August 07, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 06, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

July 29, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

July 20, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

July 16, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

June 22, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 12, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 07, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

April 29, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 17, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

April 16, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

March 31, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 13, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

March 03, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock to Present at Upcoming Investor Conferences

February 18, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 13, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

February 10, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

From Scholar Rock

Via Business Wire

Tickers SRRK

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 13, 2025

From Scholar Rock

Via Business Wire

Tickers SRRK

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.